newsfilter
← Latest News
Business Wire·

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

  • Stoke Therapeutics, Inc. granted stock options to purchase 99,050 common shares to eleven new employees as a material inducement under Nasdaq Listing Rule 5635(c)(4).
  • The grants became effective on November 16, 2026, with an exercise price of $26.63 per share equal to the closing stock price on that date.
  • Each option vests over a 4-year period, with 25% vesting on the one-year anniversary and the remainder vesting monthly at a rate of 1/48th over the subsequent 36 months.
  • The options carry a 10-year term and are subject to the terms of the 2023 Inducement Plan.
  • Stoke Therapeutics is developing zorevunersen, a first-in-class RNA medicine for Dravet syndrome, currently in a Phase 3 study using its proprietary TANGO approach.